Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials - PubMed (original) (raw)
Meta-Analysis
Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials
Lian Cui et al. Int Immunopharmacol. 2018 Sep.
Erratum in
Abstract
Numerous biologics are currently licensed for the treatment of psoriasis, including new drugs targeting interleukin-17 (IL-17) and interleukin-23 (IL-23). This meta-analysis evaluated the short-term (12-16 weeks) efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis. Twenty-one randomized clinical trials met the defined inclusion criteria. Our results showed that Ixekizumab (160 mg wk0 + 80 mg q2w) had the greatest probability of achieving both PASI 75 (RR 21.32, 95% CI 15.48-29.36, P < 0.00001) and PASI 90 response (RR 59.76, 95% CI 32.41-110.19, P < 0.00001) at the primary endpoint times, followed by Ustekinumab and Secukinumab. Regarding the safety profile, Tildtakizumab (200 mg, q4w) was safest (RR 0.88, 95% CI 0.78-0.99, P = 0.04), while Ixekizumab (160 mg wk0 + 80 mg q2w) showed highest risk for one or more AE (RR 1.26, 95% CI 1.15-1.38, P < 0.00001). However, there was no significant difference between the two biologics regarding one or more SAEs. Comparing to the biologics targeting IL-23, the pooled effect size favored the biological agents targeting IL-17 in terms of the PASI 75 (PASI 75: RR 17.28, 95% CI 14.51-20.58, P < 0.00001) and PASI 90 (RR 37.19, 95% CI 26.91-51.41, P < 0.00001). The rate of overall AEs was significantly higher (P < 0.00001) in biologics targeting the IL-17 (RR 1.18, 95% CI 1.12-1.24, P < 0.00001) compared to biologics targeting IL-23 (RR 0.97, 95% CI 0.91-1.04, P = 0.44), and with respect to one or more SAEs, no difference was seen between biologics targeting IL-17 and IL-23. This meta-analysis found that Ixekizumab was the most effective short-term treatment, but was ranked as the most risk therapeutic choice among the biologics involved in this study, while Tildtakizumab was the best alternative in the case of safety. Furthermore, it demonstrated that biologics inhibiting IL-17 were superior to biologics targeting IL-23 in terms of the efficacy, but posed higher risk at the same time. This study might help the clinicians and guideline developers to choose the optimal one among these biologics for the treatment of moderate-to-severe plaque psoriasis.
Keywords: Biologics; IL-17; IL-23; Meta-analysis; Plaque; Psoriasis.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
- A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. Bilal J, et al. J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28. J Dermatolog Treat. 2018. PMID: 29532693 Review. - Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Bai F, et al. J Immunol Res. 2019 Sep 10;2019:2546161. doi: 10.1155/2019/2546161. eCollection 2019. J Immunol Res. 2019. PMID: 31583255 Free PMC article. - Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
Molinelli E, Campanati A, Brisigotti V, Offidani A. Molinelli E, et al. Curr Pharm Biotechnol. 2017;18(12):964-978. doi: 10.2174/1389201019666180103140643. Curr Pharm Biotechnol. 2017. PMID: 29299984 Review. - Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K. Tada Y, et al. J Dermatol Sci. 2020 Jul;99(1):53-61. doi: 10.1016/j.jdermsci.2020.06.003. Epub 2020 Jun 18. J Dermatol Sci. 2020. PMID: 32600737 - Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis.
Erichsen CY, Jensen P, Kofoed K. Erichsen CY, et al. J Eur Acad Dermatol Venereol. 2020 Jan;34(1):30-38. doi: 10.1111/jdv.15879. Epub 2019 Sep 4. J Eur Acad Dermatol Venereol. 2020. PMID: 31419343
Cited by
- Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study.
Loft N, Egeberg A, Isufi D, Rasmussen MK, Bryld LE, Dam TN, Ajgeiy KK, Bertelsen T, Skov L. Loft N, et al. Acta Derm Venereol. 2023 Nov 21;103:adv12616. doi: 10.2340/actadv.v103.12616. Acta Derm Venereol. 2023. PMID: 37987625 Free PMC article. - Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis.
Klint S, Feldwisch J, Gudmundsdotter L, Dillner Bergstedt K, Gunneriusson E, Höidén Guthenberg I, Wennborg A, Nyborg AC, Kamboj AP, Peloso PM, Bejker D, Frejd FY. Klint S, et al. MAbs. 2023 Jan-Dec;15(1):2209920. doi: 10.1080/19420862.2023.2209920. MAbs. 2023. PMID: 37184136 Free PMC article. - Living with Psoriasis Vulgaris and Multi-Treatment Failure: A Patient and Dermatologist Perspective.
Spencer RK, Elhage KG, Jin JQ, Davis MS, Hakimi M, Bhutani T, Chang H, Liao W. Spencer RK, et al. Dermatol Ther (Heidelb). 2023 Apr;13(4):857-866. doi: 10.1007/s13555-023-00907-1. Epub 2023 Mar 11. Dermatol Ther (Heidelb). 2023. PMID: 36913122 Free PMC article. - Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature.
AlMutairi N, Eassa BI. AlMutairi N, et al. Postepy Dermatol Alergol. 2021 Apr;38(2):281-288. doi: 10.5114/ada.2019.91496. Epub 2020 Jan 9. Postepy Dermatol Alergol. 2021. PMID: 36751540 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous